Onkure Therapeutics Inc (OKUR)

$2.75 -0.14 (-4.84%)
Market Cap 38.83M
Revenue (ttm) 0.00
Net Income (ttm) -52.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 97,522
Avg Vol 39,582
Day's Range N/A - N/A
Shares Out 13.44M
Stochastic %K 38%
Beta 0.35
Analysts Strong Sell
Price Target $32.00

Latest News on OKUR

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 10, 2025, 4:05 PM EDT - 5 weeks ago

OnKure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

Mar 4, 2025, 8:00 AM EST - 6 weeks ago

OnKure Therapeutics to Present at Upcoming Leerink and Stifel Investor Conferences

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

Dec 10, 2024, 7:00 AM EST - 4 months ago

OnKure Announces Encouraging Preliminary Safety, Tolerability, and Pharmacokinetic (PK) Data from its First-In-Human PIKture-01 Trial of OKI-219

OnKure Announces New Date for Upcoming Investor Call

Nov 25, 2024, 5:31 PM EST - 5 months ago

OnKure Announces New Date for Upcoming Investor Call

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

Nov 1, 2024, 5:30 PM EDT - 6 months ago

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond

Oct 24, 2024, 3:31 PM EDT - 6 months ago

OnKure: Looking To Alter PI3K Inhibitor Targeting In Breast Cancer And Beyond